
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Brand Name | Status | Last Update |
|---|---|---|
| escitalopram | ANDA | 2025-11-18 |
| escitalopram oral solution | ANDA | 2025-03-05 |
| escitalopram oxalate | ANDA | 2025-10-20 |
| lexapro | New Drug Application | 2023-11-17 |
Expiration | Code | ||
|---|---|---|---|
ESCITALOPRAM OXALATE, LEXAPRO, ABBVIE | |||
| 2026-05-12 | NPP | ||

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 2 | 1 | — | 4 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 1 | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 1 | 2 | — | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Generalized anxiety disorder | D000098647 | — | — | — | — | 1 | — | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 1 | — | — | 1 |
| Drug common name | Escitalopram |
| INN | escitalopram |
| Description | Escitalopram is a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram. It has a role as an antidepressant and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a conjugate base of an escitalopram(1+). It is an enantiomer of a (R)-citalopram. |
| Classification | Small molecule |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21 |
| PDB | — |
| CAS-ID | 128196-01-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1508 |
| ChEBI ID | 36791 |
| PubChem CID | 146570 |
| DrugBank | DB01175 |
| UNII ID | 4O4S742ANY (ChemIDplus, GSRS) |






